NCT04861051RecruitingPhase 1
Understanding Ketamine's Dissociative Effects (KD Study)
Understanding Ketamine's Dissociative Effects in Epilepsy (KD Study)
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to understand how ketamine brings about dissociative symptoms.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 22 Apr 2021
- Start date
- 26 Jul 2021
- Primary completion date
- 1 Aug 2028
- Lead sponsor
- Stanford University
- Diseases
- Epilepsy
- NCT number
- NCT04861051
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- From 26 Jul 2021 to the primary completion date, 1 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior adverse ketamine response
Other illness
- Lifetime psychotic or bipolar disorder
Other
- Inability to speak, read or understand English
- Pregnant or nursing females
Who the study is looking for
- Patient in Stanford Epilepsy Monitoring Unit
- Age \>18 years old.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University, School of Medicine Coordinator of this site? Confirm its status | Palo Alto | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.